Chiseliţă D, Rusu V, Brănişteanu D, Apatachioaie I, Poiata I, Tătăruş C
Clinica Oftalmologică Iaşi.
Oftalmologia. 1997;41(2):18-24.
Analysis of the safety and efficiency of various modalities of 5-FU administration in the surgery of refractory glaucoma.
A prospective, randomized study including 36 patients with refractory glaucoma who received 5-FU in the following protocols: group A (10 patients)--intraoperative application of 50 mg 5-FU, group B (12 patients)--postoperative subconjunctival injections of 5 mg 5-FU, group C (14 patients)--intra and postoperative administration of 5-FU. Mean follow-up interval is 6 months.
Last controlled intraocular pressure is lower in C group patients (13.92 mmHg) versus group A and group B patients (< or = 15.7 mmHg). The real therapeutic success rate (intraocular pressure < or = 15 mmHg) and the qualified success rate (intraocular pressure < or = 21 mmHg) are higher in group C (85.7% and 92.8% respectively) as compared with group A and group B (50% and 82% respectively). The rate of side-effects in highest in group B and lowest in group C.
Association of intra and postoperative use of 5-FU in refractory glaucoma increases the rate of therapeutic success and a lower incidence of side-effects.
分析5-氟尿嘧啶(5-FU)不同给药方式在难治性青光眼手术中的安全性和有效性。
一项前瞻性随机研究,纳入36例难治性青光眼患者,按以下方案接受5-FU治疗:A组(10例患者)——术中应用50mg 5-FU;B组(12例患者)——术后结膜下注射5mg 5-FU;C组(14例患者)——术中及术后均给予5-FU。平均随访时间为6个月。
C组患者末次眼压控制值(13.92mmHg)低于A组和B组患者(≤15.7mmHg)。C组的实际治疗成功率(眼压≤15mmHg)和合格成功率(眼压≤21mmHg)分别为85.7%和92.8%,高于A组和B组(分别为50%和82%)。B组的副作用发生率最高,C组最低。
难治性青光眼术中及术后联合使用5-FU可提高治疗成功率并降低副作用发生率。